Abstract Prescribing anastrozole instead of tamoxifen increases initial adjuvant drug costs but there is an eventual saving as fewer patients will relapse. The effect of this saving depends on an accurate understanding of the cost of breast cancer relapse. We identified 232 patients relapsing between March 2000 and 2005. Seventy-seven were randomly selected for analysis of their entire hospital and community management costs from the date of relapse until death, or the end of the evaluation period (01/01/07). The mean cost per patient was £25,186 (95% CI £13,705-£33,821). The median survival from time of relapse was 40.07 months (range 0.5-73 months) and median total cost per patient was £31,402.62. Equating this figure with the difference in relapse rate (4.1%), initial drug cost (£4,773) gives an extra cost of £17,244/life year saved. This was the first adjuvant cost effectiveness analysis which included the community management activity of a subsequent relapse.
Introduction
Developments in adjuvant drugs such as trastuzumab, aromatase inhibitors and taxanes are giving clinicians and patients several choices following a diagnosis of early breast cancer. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial showed that anastrozole, given from diagnosis for 5 years, improved disease-free survival by 4.1% compared to 5 years tamoxifen (100 months median follow up data) [1] . Other adjuvant aromatase inhibitors studies have shown similar benefits [2] [3] [4] . These strategies, although initially expensive, reduce the risk of relapse and hence involve long-term cost savings [5] . The challenge for budget holders is to contrast the long-term fiscal gain against the higher initial costs. Notwithstanding the humanitarian issues, the key to this comparison is an accurate estimate of how much it costs to treat a patient who has relapsed. Patients require regular hospital attendances, intensive drug treatments including chemotherapy, hormone therapy, immunotherapy and analgesia, not to mention radiology, pathology and radiotherapy in addition to the enormous community support with general practitioners (GPs), district nurses and palliative care services.
Health economic analyses of anastrozole have been conducted in the past [6] , but all estimate the cost of a relapse using predictive modelling, questionnaires or interviews with clinicians [2, 3, [7] [8] [9] ]. An independent United Kingdom (UK) trial, now 6 years old, estimated hospital costs of relapsed breast cancer by sending questionnaires to UK oncologists, and estimated a cost of £12,500 per patient [10, 11] . A comprehensive study from Edinburgh, estimated a cost of £13,533 for loco-regional relapse and £13,193 for distant relapse, but collected hospital data alone, from node positive women. [12, 13] . This study reports the first analysis of the complete hospital and community costs of managing patients with relapsed breast cancer, based on actual data from a typical UK breast cancer practise.
Methods
The Bedford Breast Unit database identified 232 women with breast cancer who had relapsed between March 2000 and 2005, with loco-regional or distant disease. The patients' hospital numbers were placed in separate sealed envelopes, shuffled, and one-third (77) randomly selected by an independent worker, for detailed data collection. Data was collected until a patient's death or the predetermined end of the study in January 2007. Table 1 summarises the demographics of the entire group and selected cohort, their similarity indicating that the randomisation process was balanced. The specific cancer-related activities were derived from hospital notes, and computer, pharmacy, GP, district nurse and hospice records. Activities included; in-and outpatient activity, oncology drugs, radiology, radiotherapy, blood tests investigations, GP, district nurse and hospice visits (Table 2 ). There were no missing data, as the research team visited all GP practises, hospices, community offices and hospital departments, and ensured that all available data were collected.
Analysis and statistical considerations
The data were analysed in liaison with the Health Economics Department at Cranfield University. The median life expectancy was measured from a Kaplan-Meier life table and survival curve (Fig. 1) . Cross-checking using the XLSTAT package for consistency and normality, suggested that the distribution of the average cost per month was nonnormal and under such circumstances the median, rather than mean, was deemed a better representation. The predetermined subgroups were oestrogen receptor (ER) positivity (Allred score [4) ; human epidermal growth factor receptor 2 (HER2) over-expression; axillary node involvement and menopausal status (defined as no spontaneous mensus for 2 years, lutinising hormone, follicle stimulating hormone and oestrodiol levels or if uncertain, aged over 55 years). For comparison of the direct cost between the subgroups, the mean cost per patient was more representative.
The tariffs
The tariffs of the UK National Health Service (NHS) procedures, outpatient visits, nights in hospital and investigations were deduced from the existing NHS Reference Costs [14] . Radiotherapy cost per fraction was based on the national average unit cost [14] . GP and district nurse visits costs were taken from primary care trust reference costs [14] . Hospital drug costs included value added tax (VAT), and were the actual amount charged for each. Community drug tariffs (excluding VAT) and hospice drug tariffs (including VAT) were based on the British National Formulary [15] .
Results
Of the 77 patients whose data sets were analysed in this study, 52 (67.5%) had died of metastatic breast cancer by the end of the data collection point, January 2007, with a median survival of 3.34 years, (40.07 months, Fig. 1 ). The first site of relapse was distant in 51 patients (66%), and loco regional in 26 (34%). The average time from initial diagnosis to relapse was 71.2 months (range 4-173 months).
The total hospital and community cost of managing the 77 patients from the time of their relapse until death or to the end of the evaluation period was £1,939,329. Based on the total number of patient-months within the assessment period Nearly a third (30.3%) of the cost of a relapse lay in the community, and 69.7% in the hospital setting. There was no difference in those axillary node positive or negative patients, or between HER2 over-expressers or not, but in this study cohort only 7 of the 16 HER2 over-expressers received trastuzumab.
This cost of relapse data can be used to estimate the cost-effectiveness of adjuvant anastrozole. Based on the absolute difference in disease-free survival at 10 years post-randomisation, between 5 years adjuvant tamoxifen or 5 years adjuvant anastrozole was 4.1% [1] , the number needed to be treated to avoid one relapse was 24.4 patients (1/4.1%). Table 3 demonstrates the extra initial costs of anastrozole over tamoxifen based on national tariffs. The difference in drug and bone density costs between 5 years tamoxifen and 5 years anastrozole strategies was £4,773 [15] . Consequently it costs £116,415 to prevent one patient relapsing. However, subtracting the median cost of treating a patient with relapsed breast cancer gained from this study (£31,403), gives net cost estimate of £85,012, or £3,485 per patient treated with anastrozole.
The median survival of the relapsed women in this study was 2.72 years, but in order to calculate the cost per life year gained, it was necessary to estimate the life expectancy of patients who do not relapse compared to those who do. This was estimated using a Markov Model and fitting Weibull Curves to the analysis of the ATAC trial (68 months data) [6] . This methodology required a key assumption that the benefit of anastrozole would carry over to 5 years following the end of treatment, which was later verified in the ATAC trial (100 months data) publication [1] . Extrapolated over 25 years, the life expectancy of a representative 64 years old female who did not suffer a breast cancer relapse was 13.01 years compared to 8.08 years for a female who did suffer a relapse. The estimated difference in life expectancy between relapsed and non-relapsed patients is therefore 4.93 years. The estimated incremental cost to prevent a breast cancer relapse if anastrozole is used upfront for 5 years instead of tamoxifen, is £17,244 per patient life year gained.
Discussion
The strength of this retrospective study lies in the comprehensiveness of the data extracted from a breast cancer population treated within a standard UK management framework. Collecting the complete data, from both hospital and community sources, required an enormous degree of co-operation from a wide range of professional groups. This could only practically be possible around a single institution. Paradoxically, this is also the basis of a potential criticism, as a single-institution study may be subject to skews in local population demographics or medical practise.
The demographics of the North Bedfordshire population appear to be fairly typical for the UK. The average age was similar to the national average, as was the single, separated and widowed population. The percentage of people with British citizenship (91.4 vs. 87.5%), and those born in the UK (93.0 vs. 91.1%) were also similar. There was a slightly higher percentage of the population working (42.6 vs. 40.1%), and fewer unemployed (2.6 vs. 3.4%), but a similar percentage who achieved higher educational qualifications (18.9 vs. 19.8%) [16] . Breast cancer management adhered to West Anglia Cancer Network guidance, which has been developed from national advisory documents [17] . Any deviation from this guidance would require formal discussion and written approval, which has been established for 9 years.
The median overall survival for the patients relapsing at our institution (40.7 months), was higher than the 10-20 months Months since relapse Proportion of patients surviving reported with first-line metastatic studies in the UK and Europe evaluating metastatic chemotherapy regimens [18, 19] , but it was fairly comparable with the 20-30 months reported within first-line metastatic aromatase versus tamoxifen studies [9, 20] . Although the median figure of £31,403 (Table 4) for treating a relapse is higher than previous UK estimates, the data is more recent and included the 30% of the community cost not previously collected. The results represent the last 6 years of management activity, and are therefore likely to underestimate future costs. Newer biological agents such as oral tyrosine kinase inhibitors and anti-angiogenesis drugs will substantially add to drug costs, but as they keep relapsed patients alive for longer, this will also increase non-drug costs. Even the full impact of trastuzumab, in this data set, was not fully appreciated. Routine use of trastuzumab in the metastatic setting within our institution was introduced in November 2006; almost half way through the evaluation period. This meant that only 7 of the 16 HER2 over-expressing patients received trastuzumab as part of their metastatic management. The average cost of the trastuzumab in the treated patients was £15,834.62. According to the original published metastatic breast cancer trastuzumab trials data, these patients on average, could have lived 5 months longer [21, 22] . Therefore, if the remaining nine patients had received trastuzumab, and each lived 5 months longer, this factor alone would have increased the total cost per patient to over £34,200.
The estimated cost per life year gained if anastrozole is used at upfront for 5 years instead of tamoxifen, compares favourably to the threshold used by the National Institute of Clinical Excellence of £30,000 per quality adjusted life year [23] . However, this is a simple analysis and assumes that patients receive all 5 years of treatment with anastrozole or tamoxifen, whereas in practise some patients would relapse within the first 5 years and thus would not receive the full 5 years worth of treatment. Taking this into account would decrease the incremental cost per life year gained. In addition, the analysis does not take into account differences in the adverse event profiles between the two drugs.
Although extrapolation of the data can provide a useful forecast, it highlights the pitfalls of costing studies. Newer and better drugs for the treatment of metastatic disease are constantly emerging, creating costly new challenges. Nevertheless, the cost per patient of adjuvant anastrozole seems very reasonable considering the devastation caused by a breast cancer relapse. In daily clinical practise, the cost-effectiveness of anastrozole may also be greater as many UK oncologists often select patients who have a good prognosis, and who could switch from tamoxifen at 2 years, as in the ARNO study. These include patients who do not have pathological prognostic factors which predict a higher and earlier relapse rate, such as higher histological grade, presence of vascular invasion, tumour size and number of positive axillary nodes [24] , and biological molecular markers such Cerb2, Ki67, CYP-2D6, level of oestrogen receptor positivity and progesterone receptor negativity [24, 25] . However, even if patients have a good prognosis, patients may also be better off on anastrozole if they have a history of thromboembolic disease or risk of uterine carcinoma [24] [25] [26] . More recently, the roles played by quality of life, tolerance and patient preference also have important implications on the choice of adjuvant drug [5] . Nevertheless, despite these issues, there are savings to be made from delaying the start of anastrozole, although this may not be as great as anticipated. The difference in event-free survival between anastrozole and tamoxifen, albeit measured at 28 months post-switch and based on patients who have successfully completed 2-3 years adjuvant therapy for early breast cancer. Based on the same methodology used in this study results in an incremental cost of £11,173 per life year. There are also some patients who relapse before 2 years, and who may not have done so if anastrozole was used upfront, and these patients are expensive to manage. Moreover, if the difference in eventfree survival was measured from the start of treatment, then the results may be different. As such, the results should not be used to support a treatment strategy of starting with tamoxifen with the intention of changing to anastrozole after two or more years, rather the results show a continuing cost advantage attached to using anastrozole after treatment with tamoxifen. This study's comprehensive estimate of the cost of relapse contributes to the body of published evidence, and adds accuracy and credence to the future of cost-effectiveness estimates of adjuvant breast cancer therapies. The already high, and escalating cost of treating patients with relapse breast cancer, confirms the humanitarian sentiments that it is better to prevent relapse in the first place. The authors intend to repeat the same data collection exercise every 2 years using the same methodology to give an ongoing estimate as the newer biological agents evolve into clinical practise.
